Indivior PLC — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Market Cap: $3.8BPipeline: 2 drugs (2 Phase 3)Founded: 2014Employees: 1000-5000HQ: North Chesterfield, United States

Overview

Indivior is a mission-driven, publicly traded biopharmaceutical company dedicated to saving lives from the devastating impacts of substance use disorders and mental illness. Its strategic foundation is built upon a 25-year legacy of innovation in buprenorphine-based medication-assisted treatment (MAT), most notably through the commercialization of SUBLOCADE®, a once-monthly injectable that has become the standard of care. Following a strategic redomiciliation to the U.S. and resolution of legacy legal matters, the company is now executing a focused growth strategy to defend its core OUD franchise while advancing a promising pipeline targeting schizophrenia and cocaine use disorder.

Substance Use DisordersSchizophrenia

Technology Platform

Proprietary drug delivery systems for long-acting injectable and sublingual formulations, centered on optimizing buprenorphine pharmacokinetics to improve adherence and outcomes in chronic, relapsing conditions.

Pipeline

2

2 drugs in pipeline2 in Phase 3

Drug	Indication	Stage	Watch
SUBLOCADE	Opioid Use Disorder	Phase 3
SUBLOCADE	Opioid Use Disorder	Phase 3

Funding History

1

IPOUndisclosedUndisclosedJul 24, 2014

FDA Approved Drugs

4

OPVEENDAMay 22, 2023

PERSERIS KITNDAJul 27, 2018

SUBLOCADENDANov 30, 2017

Opportunities

Significant opportunity to convert the ~1.5 million U.S.

patients on oral buprenorphine to long-acting injectable therapies like SUBLOCADE®, driving sustained core growth.

Pipeline assets RBP-6300 and INV-202 offer potential entry into the multi-billion dollar schizophrenia market and a first-in-class therapy for cocaine use disorder, respectively, representing major expansion avenues.

Risk Factors

Clinical and commercial execution risks for key pipeline candidates (RBP-6300, INV-202) are high.

Intensifying competition in the OUD space, particularly from Camurus's Brixadi®, threatens market share and pricing for the core SUBLOCADE® product.

The company remains subject to stringent regulatory oversight and potential pricing pressures.

Competitive Landscape

In OUD, Indivior faces direct competition from Camurus's Brixadi® injection and a deep generic oral buprenorphine market. In schizophrenia, its pipeline candidate RBP-6300 will enter a crowded LAI antipsychotic market dominated by large pharma players. Its competitive edge lies in deep addiction treatment expertise, a specialized commercial footprint, and proprietary long-acting delivery technology.